Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension.
The hypotensive action of guanfacine and alpha-methyldopa has been compared in 30 patients wth moderate essential hypertension. After 2 weeks of placebo treatment, the patients were randomly allocated to a 12 week treatment with either of the two drugs. The treatment was started with guanfacine, 1 mg twice daily p.o., or alpha-methyldopa, 250 mg three time a day p.o. This dose of guanfacine was able to induce a satisfactory control of blood pressure in all patients while the dose of alpha-methyldopa was gradually increased to a predetermined maximum daily dose (2 g) in those patients with unsatisfactory blood pressure control, i.e., systolic blood pressure above 160 mmHg and diastolic above 95 mmHg. Then the two treatments were dicontinued for one week. Both drugs induced a significant reduction of systolic and diastolic blood pressure. However, guanfacine induced a more marked decrease in systolic blood pressure after the 14th day of treatment while the reduction of diastolic blood pressure was significantly higher only at the end of the final wash-out period, thus indicating a longer lasting effect of guanfacine as compared to alpha-methyldopa. Two patients treated with guanfacine developed dryness of the mouth and three of those in the alphamethyldopa group complained of excessive sedation.
D000367:Age Factors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D001827:Body Height; D001830:Body Surface Area; D001835:Body Weight; D004341:Drug Evaluation; D005260:Female; D016316:Guanfacine; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D010648:Phenylacetates / Q000627:therapeutic use
D000959:Antihypertensive Agents; D006146:Guanidines; D010648:Phenylacetates; D016316:Guanfacine; D008750:Methyldopa